Doxepine-bupropion

Doxepin
Type antidepressant
Group TCA
links
ATC-code N06AA12
Medscape Doxepin
PubChem 3158
PubMed Doxepin
Drugs.com doxepin
Kompas (Dutch) Doxepin
Wikipedia Doxepin
Bupropion
Type Antidepressant
Group other
links
ATC-code N06AX12
Medscape Bupropion
PubChem 444
PubMed Bupropion
Kompas (Dutch) Bupropion
Wikipedia Bupropion

Switch medication from doxepin to bupropion.

Nietinrijdenbord.png Stop doxepin
  • Before day 1: gradually reduce dosage of doxepin to a maximum of 100 mg/day, when this dosage is > 100 mg/day.
  • Day 1: reduce dosage of doxepin to 50 mg/day.
  • Day 8: reduce dosage of doxepin to 25 mg/day.
  • Day 15: stop administration of doxepin.
Eenrichtingbord.png Start bupropion
  • Day 8: simultaneously start administration of bupropion in a dosage of 150 mg/day and continue administration of doxepin according to the scheme above.
  • Day 15: stop administration of doxepin and continue administration of bupropion.
  • Day 23: if necessary increase the dosage of bupropion.
Infobord.png More information
  • Bupropion is a strong inhibitor of CYP2D6, which metabolizes doxepin.
  • The concomitant use of bupropion and tricyclic antidepressants (TCAs) may potentiate the risk of seizures. These agents are all epileptogenic and may have additive effects on the seizure threshold.
  1. ↑ 1.01.11.21.31.4 KNMP; Informatorium Medicamentorum 2015; Monografie "doxepine" (Dutch)
  2. ↑ NVZA; Toxicology.org; Monografie 63 (dutch)
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.